OOIR: Observatory of International Research

Papers

(The H4-Index of Alzheimers Research & Therapy is 46. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Structural brain improvements following individually tailored serious exergame-based training in mild neurocognitive disorders: exploratory randomized controlled trial	239
A novel electric field approach for improving cognitive function through ameliorating cell-specific pathology in P301S tauopathy mice	229
Serum phosphorylated tau protein 181 and neurofilament light chain in cognitively impaired heart failure patients	171
Prominent tauopathy and intracellular β-amyloid accumulation triggered by genetic deletion of cathepsin D: implications for Alzheimer disease pathogenesis	157
Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy	156
Association between antemortem plasma and structural MRI biomarkers and postmortem tau pathology in the Mayo Clinic Study of Aging	155
A biomarker-validated time scale in years of disease progression has identified early- and late-onset subgroups in sporadic Alzheimer’s disease	134
Linking eye movements, pupil responses, and brain networks in early cognitive decline	122
Associations of adherence to a healthy sleep pattern with the dementia risk in the UK biobank	121
Issues and recommendations for the residual approach to quantifying cognitive resilience and reserve	117
Moderating role of executive function in the relationship between specific white matter changes and long-term delayed recall in aMCI patients	116
Recent molecular insights and biosensor-based diagnostic technologies for hyperphosphorylated Tau in Alzheimer's disease	106
Correction: 18F-FDG PET can effectively rule out conversion to dementia and the presence of CSF biomarker of neurodegeneration: a real-world data analysis	103
Effect of the ABCA1 agonist CS-6253 on amyloid-β and lipoprotein metabolism in cynomolgus monkeys	97
Investigating the Aβ and tau pathology in autosomal dominant Alzheimer’s disease: insights from hybrid PET/MRI and network mapping	93
Anti-tau VHH therapy against PHF6: a safe approach to slowing the phenotype of tau pathology	90
Diagnostic performance of verbal fluency measures: a cross-sectional study in the stages of cognitive continuum	90
Development of a Japanese polygenic risk score model for amyloid-β PET imaging in Alzheimer’s disease	90
Comparing a pre-defined versus deep learning approach for extracting brain atrophy patterns to predict cognitive decline due to Alzheimer’s disease in patients with mild cognitive symptoms	85
Genetic and clinical landscape of Chinese frontotemporal dementia: dominance of TBK1 and OPTN mutations	83
An association of CSF apolipoprotein E glycosylation and amyloid-beta 42 in individuals who carry the APOE4 allele	83
Automated high-throughput quantification of plasma p-tau217 and APOE-ε4 for Alzheimer’s disease diagnosis and cognitive decline in a memory cohort	81
Impact of gender on the willingness to participate in clinical trials and undergo related procedures in individuals from an Alzheimer’s prevention research cohort	81
High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer’s disease	75
Greater baseline cortical atrophy in the dorsal attention network predicts faster clinical decline in Posterior Cortical Atrophy	71

ISX9 activates the Wnt/β-catenin signaling pathway and exerts neuroprotective effects in Alzheimer’s disease	71
Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology	71
Granulovacuolar degeneration bodies are independently induced by tau and α-synuclein pathology	66
Stress-induced alteration of small extracellular vesicles drives amyloid-beta sequestration and exacerbates Alzheimer’s disease pathogenesis	66
Amyloid-β PET scans, economic strain and financial decision-making among persons with cognitive impairment and care partners: a mixed-methods analysis of the CARE-IDEAS study	64
Global and domain-specific cognitive intraindividual variability associations with neurodegenerative diagnoses and postmortem pathologies	62
The economic burden of subjective cognitive decline, mild cognitive impairment and Alzheimer's dementia: excess costs and associated clinical and risk factors	62
Longitudinal evaluation of common and unique brain-networks in variants of primary progressive aphasia	60
Cornuside alleviates cognitive impairments induced by Aβ1−42 through attenuating NLRP3-mediated neurotoxicity by promoting mitophagy	59
Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis	59
A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects wi	58
Linking oxysterols and different stages of mild cognitive impairment: insights from gut metabolites and N6-methyladenosine	57
Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer’s disease	56
Fluid biomarkers for neurodegenerative diseases: a comprehensive update	54
A multiscale brain network model links Alzheimer’s disease-mediated neuronal hyperactivity to large-scale oscillatory slowing	53
Impact of effective connectivity within the Papez circuit on episodic memory: moderation by perivascular space function	52
Whole-brain modeling of the differential influences of amyloid-beta and tau in Alzheimer’s disease	51
CEST imaging combined with 1H-MRS reveal the neuroprotective effects of riluzole by improving neurotransmitter imbalances in Alzheimer’s disease mice	50
Cerebral Aβ deposition precedes reduced cerebrospinal fluid and serum Aβ42/Aβ40 ratios in the AppNL−F/NL−F knock-in mouse model of Alzheimer’s disease	49
Reduced plasma TIA-1: bridging established pathology and novel biomarker potential	48
Real—world application of lecanemab in early—stage alzheimer's disease: a single—center prospective cohort analysis	47
Tau seeding activity in the cerebrospinal fluid of Alzheimer disease patients predicts short-term cognitive decline	46